The European CAR‐T map—Current status and future directions to improve access to CAR T‐cell therapy for hematologic malignancies
Elise R. A. Pennings(Lymphoma Study Association), Marie José Kersten(Lymphoma Study Association), Jana Mihályová(University of Ostrava), Florence Broussais(Institut Calot), Olga Millán(RUAG (Germany)), Samantha Nier(Advocates for Youth), Robin Doeswijk(European Hematology Association), Natacha Bolaños(HOPE Clinic), Carmen Sanges(Augenklinik Universitätsklinikum Würzburg), Frederick W. Thielen(University Medical Center Freiburg), Caroline Dreuillet(Institut National du Cancer), Michael Hudecek(Augenklinik Universitätsklinikum Würzburg), Ulrich Jaeger(Medical University of Vienna), Michaela Horňáková(University of Ostrava), Barbara Huber(Augenklinik Universitätsklinikum Würzburg), Catherine Thieblemont(Université Paris Cité), Lutgart Roux‐Opstaele(Institut National du Cancer), Carin A. Uyl‐de Groot(Erasmus University Rotterdam), Roman Hájek(University of Ostrava), Julio Delgado(Hospital Clínic de Barcelona), Yolanda Cabrerizo(European Hematology Association), Eglys Gonzalez‐Marcano(International Society for Optics and Photonics), Solène Clavreul(European Federation of Allergy and Airways Diseases Patients Associations)
Cited by 2
Related Papers
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907
Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
|American Journal of Hematology|2019|472
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation
|New England Journal of Medicine|2020|418
Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation
|New England Journal of Medicine|2020|345